| abstract |
The invention pertains to fused cyclic compounds having the formula, n n nwherein G is an optionally substituted aryl or heterocyclo, L is an optional linker, M is a bond, O, CR 7 R 7′ or NR 10 , and M′ is a bond or NR 10 , with the proviso that at least one of M or M′ must be a bond; E is C=Z 2 , CR 7 CR 7′ , SO 2 , P═OR 2 , or P═OOR 2 ; Z 1 is O, S, NH, or NR 6 ; Z 2 is O, S, NH, or NR 6 ; A 1 is CR 7 or N; A 2 is CR 7 or N; Y is J-J′-J″ where J is (CR 7 R 7′ )n and n=0-3, J′ is a bond or O, S, S═O, SO 2 , NH, NR 6 , C═O, OC═O, NR 1 C═O, CR 7 R 7′ , C═CR 8 R 8′ , R 2 P═O, OPOOR 2 , OPO 2 , OSO 2 , C═N, NHNH, NHNR 6 , NR 6 NH, N=N, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo or aryl or substituted aryl, and J″ is (CR 7 R 7′ ) n and n=0-3; and W, Q, R 2 , R 6 , R 7 , R 7′ , R 8 , R 8′ , R 9 , R 9′ , and R 10 are as defined in the specification and/or claims herein, to methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and to pharmaceutical compositions containing such compounds. |